Fibrocell Science Inc (NASDAQ:FCSC) dropped 0.7% during mid-day trading on Monday . The company traded as low as $2.85 and last traded at $3.02. Approximately 5,354 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 894,736 shares. The stock had previously closed at $3.00.
FCSC has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Fibrocell Science from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a report on Tuesday, May 15th. HC Wainwright set a $30.00 price target on shares of Fibrocell Science and gave the stock a “buy” rating in a report on Thursday, May 10th. Griffin Securities reissued a “buy” rating on shares of Fibrocell Science in a report on Monday, April 2nd. Finally, ValuEngine raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $20.25.
The firm has a market capitalization of $17.58 million, a PE ratio of -0.34 and a beta of 0.38.
Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.30. sell-side analysts forecast that Fibrocell Science Inc will post -1.83 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC bought a new stake in shares of Fibrocell Science during the 4th quarter valued at about $393,000. Anson Funds Management LP bought a new stake in shares of Fibrocell Science during the 4th quarter valued at about $287,000. Sabby Management LLC bought a new stake in shares of Fibrocell Science during the 4th quarter valued at about $733,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of Fibrocell Science by 100.0% during the 1st quarter. Point72 Asset Management L.P. now owns 400,000 shares of the company’s stock valued at $236,000 after purchasing an additional 200,000 shares in the last quarter.
About Fibrocell Science
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.